Open Access
Issue
E3S Web of Conf.
Volume 215, 2020
International Scientific Conference on Biotechnology and Food Technology (BFT-2020)
Article Number 05005
Number of page(s) 6
Section Biomedical Technology and Biopharmaceuticals
DOI https://doi.org/10.1051/e3sconf/202021505005
Published online 02 December 2020
  1. G. Housman, S. Byler, S. Heerboth, et al. Drug resistance in cancer: an overview, Cancers 6, 3, 1769-1792 (2014) [CrossRef] [PubMed] [Google Scholar]
  2. J.P. Gillet, M.M. Gottesman, Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1, Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 15, 1-2, 2-4 (2012) [Google Scholar]
  3. A.I. Svirnovsky, S.A. Grigorovich, Pleiotropic resistance of tumor cells to therapeutic effects in B-cell lymphoproliferative diseases, Medical news 9, 5-16 (2005) [Google Scholar]
  4. S.C. Nicklisch, S.D. Rees, A.P. McGrath, et al. Global marine pollutants inhibit P-glycoprotein: Environmental levels, inhibitory effects, and cocrystal structure, Science advances 2(4), e1600001 (2016) [CrossRef] [PubMed] [Google Scholar]
  5. A. Palmeira, M.H. Vasconcelos, A. Paiva, et al. Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones, Biochemical pharmacology 83, 1, 57-68 (2012) [CrossRef] [PubMed] [Google Scholar]
  6. N.A. Colabufo, M. Contino, F. Berardi, et al. A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents, Toxicology in vitro 25, 1, 222-230 (2011) [CrossRef] [Google Scholar]
  7. A. Talevi, Multi-target pharmacology: possibilities and limitations of the «skeleton key approach» from a medicinal chemist perspective, Front Pharmacol. 6, 205, 1-7 (2015) [CrossRef] [PubMed] [Google Scholar]
  8. D.S. Novikova, A.V. Garabadzhiu, G. Melino, N.A. Barlev, V.G. Tribulovich, Small-molecule activators of AMP-activated protein kinase as modulators of energy metabolism, Russ. Chem. Bull. 64, 7, 1497-1517 (2015) [CrossRef] [Google Scholar]
  9. T.A. Grigoreva, D.S. Novikova, A.V. Petukhov, M.A. Gureev, A.V. Garabadzhiu, G. Melino, N.A. Barlev, V.G. Tribulovich, Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors, Bioorg. Med. Chem. Lett. 27, 5197-5202 (2017) [CrossRef] [PubMed] [Google Scholar]
  10. T.A. Grigoreva, A.V. Garabadzhiu, V.G. Tribulovich, Diastereotopic derivatives of chiral alkoxyisoindolinones, Russ. J. Gen. Chem. 86, 11, 2454–2461 (2016) [CrossRef] [Google Scholar]
  11. D.S. Novikova, T.A. Grigoreva, G.S. Ivanov, G. Melino, N.A. Barlev, V.G. Tribulovich, Activating effect of 3-benzylidene oxindoles on AMPK: from computer simulation to high-content screening, Chem. Med. Chem. 15 (2020) [CrossRef] [Google Scholar]
  12. O. Fedorova, A. Daks, V. Petrova, A. Petukhov, L. Lezina, O. Shuvalov, P. Davidovich, D. Kriger, E. Lomert, D. Tentler, V. Kartsev, B. Uyanik, V. Tribulovich, O. Demidov, G. Melino, N.A. Barlev, Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis, Cell Cycle 17, 15, 1917-1930 (2018) [CrossRef] [PubMed] [Google Scholar]
  13. M. Krasavin, M.A. Gureyev, D. Dar’in, O. Bakulina, M. Chizhova, A. Lepikhina, D. Novikova, T. Grigoreva, G. Ivanov, A. Zhumagalieva, A.V. Garabadzhiu, V.G. Tribulovich, Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction, Bioorg. Med. Chem. 26, 9, 2651-2673 (2018) [CrossRef] [PubMed] [Google Scholar]
  14. D.J. Booser, G.N. Hortobagyi, Anthracycline antibiotics in cancer therapy. Focus on drug resistance, Drugs 47, 2, 223-258 (1994) [CrossRef] [PubMed] [Google Scholar]
  15. S.M. He, R. Li, J.R. Kanwar, S.F. Zhou, Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1), Current medicinal chemistry 18, 3, 439-481 (2011) [CrossRef] [PubMed] [Google Scholar]
  16. T. Grigoreva, A. Romanova, A. Sagaidak, S. Vorona, D. Novikova, V. Tribulovich, Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors, Bioorganic & Medicinal Chemistry Letters 30, 18, 127424 (2020) [CrossRef] [PubMed] [Google Scholar]
  17. M. Gureev, D. Novikova, T. Grigoreva, S. Vorona, A. Garabadzhiu, V. Tribulovich, Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein–protein interaction, J. Comput. Aided. Mol. Des. 34, 1, 55-70 (2020) [CrossRef] [PubMed] [Google Scholar]
  18. T.A. Grigoreva, D.S. Novikova, M.A. Gureev, A.V. Garabadzhiu, V.G. Tribulovich, Amino acids as chiral derivatizing agents for antiproliferative substituted N-benzyl isoindolinones, Chirality 30, 6, 785-797 (2018) [CrossRef] [PubMed] [Google Scholar]
  19. D.S. Novikova, T.A. Grigoreva, A.A. Zolotarev, A.V. Garabadzhiu, V.G. Tribulovich, Advanced palladium free approach to the synthesis of substituted alkene oxindoles: Via aluminum-promoted Knoevenagel reaction, RSC Advances 8, 60, 34543-34551 (2018) [CrossRef] [Google Scholar]
  20. D.D. Orlova, D.S. Novikova, A.V. Garabadzhiu, V.G. Tribulovich, A study on hydrolytic stability of isatin N-Mannich bases, Russ. J. Gen. Chem. 88, 1, 48–56 (2018) [CrossRef] [Google Scholar]
  21. P. Davidovich, D. Novikova, V. Tribulovich, S. Smirnov, V. Gurzhiy, G. Melino, A. Garabadzhiu, First X-ray structural characterization of isatin Schiff base derivative. NMR and theoretical conformational studies, J. Mol. Struct. 1075, 450–455 (2014) [CrossRef] [Google Scholar]
  22. X. Yang, J. Shen, Y. Gao, et al. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of Pglycoprotein and enhancing apoptosis, Int. J. Cancer 137, 8, 2029-2039 (2015) [CrossRef] [PubMed] [Google Scholar]
  23. J. Wang, N. Seebacher, H. Shi, Q. Kan, Z. Duan, Novel strategies to prevent the development of multidrug resistance (MDR) in cancer, Oncotarget 8, 48, 84559-84571 (2017) [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.